OVARIAN CANCER

This study tested whether adding a specialized geriatric care team to standard cancer treatment could help older patients. It involved 792 patients aged 70 and older with various advanced cancers. The goal was to see if this coordinated care approach improved survival and quality…

This was a first-in-human study to find a safe dose of a new experimental cancer drug called SNB-101. The drug, a nanoparticle form of an existing chemotherapy, was given by IV to 21 patients with advanced solid tumors that had stopped responding to standard treatments. The main …

This study aimed to see if robot-assisted surgery is better than standard minimally invasive surgery for women with cervical, uterine, or ovarian cancer. It directly compared the two techniques in 386 patients, focusing on recovery time, complications, and quality of life after s…

This study tested whether adding an experimental drug called BD0801 to standard chemotherapy works better than chemotherapy alone for women with recurrent ovarian cancer that has stopped responding to platinum-based drugs. It involved 421 women whose cancer returned within 6 mont…

This study tested whether adding an experimental drug called TJ004309 to an existing immunotherapy (atezolizumab) could help control advanced cancers that have stopped responding to standard treatments. It involved 25 patients with specific types of advanced solid tumors, includi…

This study tested whether zafirlukast, a drug approved for asthma, could help control early signs of ovarian cancer returning. It involved a small group of patients whose only sign of relapse was a rising blood marker (CA-125), with no visible tumors on scans. The main goal was t…

This first-in-human study tested a new oral drug called RP903 in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study focused on specific cancers, including ovar…

This study tested an experimental drug called mirvetuximab soravtansine for women with recurrent ovarian, peritoneal, or fallopian tube cancers that had previously responded well to platinum-based chemotherapy. The drug is designed like a 'smart bomb' to target and kill cancer ce…

This study aimed to find the most suitable first chemotherapy treatment for older, more vulnerable women with advanced ovarian cancer. It compared three different drug schedules to see which one was most successful at delivering a full course of treatment without causing severe s…

This early-stage trial tested a new oral drug, VS-6766, given alone and later combined with another drug called everolimus. The main goal was to find safe and tolerable dosing schedules for patients with advanced solid tumors or multiple myeloma that had stopped responding to sta…

This early-stage trial tested a new immunotherapy called ELI-002 in 25 people with pancreatic, colorectal, lung, and other cancers that have specific KRAS mutations. The treatment was given after standard therapy to target any remaining cancer cells and prevent recurrence. Resear…

This early-stage study tested a new immunotherapy drug called CUE-102 in patients with advanced cancers that had returned or spread after standard treatments. The main goals were to find a safe dose and see how the body processes the drug. It involved 42 adults with specific type…

This study tested whether adding a drug called apatinib to a standard chemotherapy (etoposide) could help control ovarian cancer that had stopped responding to platinum-based treatments. It involved 35 women with advanced ovarian cancer to see if the combination was effective and…

This study tested a mobile app designed to help patients and doctors better manage advanced ovarian cancer. The app tracked patients' symptoms and health data, then used artificial intelligence to suggest care steps. It aimed to improve communication and help catch problems early…

This study tested if it was safe to give an immunotherapy drug called nivolumab directly into the abdomen (intraperitoneal) after major surgery and heated chemotherapy (HIPEC) for advanced ovarian cancer. The main goal was to find the safest dose and see how well patients tolerat…

This study tested whether adding new immunotherapy drugs to standard chemotherapy was safe and practical for patients with advanced ovarian cancer. It involved 69 patients whose cancer was too advanced for immediate surgery. Researchers compared chemotherapy plus one immunotherap…

This study tested an experimental drug called nirogacestat in patients with a rare type of ovarian cancer (granulosa cell tumor) that had returned after prior treatment. The goal was to see if the drug could shrink tumors and control the disease. The trial enrolled 53 adults whos…

This study tested a new oral medication called IMP4297 for women with advanced ovarian cancer that has a specific genetic change (BRCA mutation) and has stopped responding to at least two standard treatments. The main goal was to see if the drug could shrink tumors and control th…

This study tested a new drug called ZN-c3, both by itself and combined with an existing drug (niraparib), for women with advanced ovarian cancer that had stopped responding to platinum chemotherapy. The main goals were to find safe doses and see if the treatments could shrink tum…

This study tested a new combination of two drugs, NT-I7 and pembrolizumab, for people with advanced solid tumors that had returned or stopped responding to prior therapies. The main goals were to find a safe dose and see if the combination could shrink tumors in several hard-to-t…

This study tested a new drug called SL-172154, given alongside one of two standard chemotherapy drugs, in people with ovarian cancer that had stopped responding to platinum-based treatments. The main goals were to find a safe dose and see if the combinations showed early signs of…

This study tested the safety and effectiveness of combining two drugs, pembrolizumab and lenvatinib, in people with advanced solid tumors that had stopped responding to standard treatments. It involved 611 participants with cancers like triple-negative breast, ovarian, gastric, c…

This study tested new blood markers and calculation tools to help doctors better tell the difference between benign (non-cancerous) and malignant (cancerous) ovarian tumors before surgery. It involved 221 women who were scheduled for surgery to remove an ovarian cyst that was tho…

This study tested whether a special green dye could help surgeons see the first lymph nodes that ovarian cancer might spread to. Researchers injected the dye into the ovaries of 48 women during surgery to see if it would travel to and highlight these key lymph nodes. The goal was…

This study tested a new, non-invasive method to detect ovarian cancer earlier. Researchers used a special light technique on blood and tissue samples from 160 women with suspected or confirmed ovarian cancer. The goal was to see if this light test could accurately spot cancer and…

This study aimed to find the best way to prevent ovarian cancer in women at high genetic risk. It compared two approaches: preventive surgery to remove the ovaries and fallopian tubes, or close monitoring with a special blood test (CA-125) and ultrasounds. Researchers followed wo…

This study tested whether giving a single low dose of the drug esketamine during surgery could help prevent depression afterwards in women with ovarian cancer. Researchers compared esketamine to a placebo (saltwater) in 568 patients to see if it reduced depressive symptoms, impro…

This study tested whether acupressure, a technique using finger pressure on specific body points, could help reduce severe fatigue in women who have completed treatment for ovarian cancer. It involved 171 survivors who reported significant fatigue. Researchers measured changes in…

This study aimed to find the best way to prevent severe nausea and vomiting caused by a common chemotherapy regimen for gynecologic cancers like ovarian and cervical cancer. Researchers tested whether adding a drug called aprepitant to the standard two-drug anti-nausea treatment …

This study looked at how completely surgeons remove fallopian tubes during ovary removal surgery. Researchers examined tissue samples from 115 women to see if any fallopian tube tissue was left behind. The goal was to understand surgical quality and potentially create better trai…

This study observed how Chinese patients with ovarian or prostate cancer tolerated the cancer drug olaparib during regular medical care. Researchers followed 1,018 patients for 6-12 months to track side effects and treatment patterns. The goal was to understand the drug's safety …

This study tested different ways to encourage people to get genetic testing for breast and ovarian cancer risk. Researchers sent messages to patients and alerts to doctors to see which method worked best to get more people tested. The goal was to help more people, especially from…

This study tested a new automated system to see if it could grow cancer cells from patients with advanced metastatic cancer inside chicken eggs. The goal was to create a faster, cheaper research model to help scientists study cancer and test potential drugs. The study involved 10…

This study tested two new methods to encourage people at higher risk for hereditary cancers to get recommended genetic testing. Over 800 participants in Michigan were randomly assigned to either use a special website, receive two coaching phone calls, or get standard information.…

This study tested a digital tool designed to help cancer survivors learn about and decide whether to get genetic testing for hereditary cancer risk. Researchers wanted to see if this smart technology was easy to use and if it encouraged more people to get tested. They compared th…

This study looked at cancer cells that break away from ovarian tumors and travel in the bloodstream. Researchers collected blood samples from 30 women with advanced ovarian cancer to examine these cells in detail. The goal was to understand if these cells can help predict how the…

This study looked at whether the cancer drug olaparib causes a folic acid (folate) deficiency in patients with advanced ovarian or breast cancer. Researchers wanted to see how often this happens and if giving patients a folic acid vitamin supplement could prevent the deficiency. …

This study aims to understand how common a specific protein marker called HER2 is in recurrent advanced endometrial, ovarian, and cervical cancers in Taiwan. Researchers will look back at the medical records and tissue samples of about 509 patients to see how many have high level…